Along the same line, PALOMA-4 was a phase III, double-blind, randomised (1:1) clinical trial which included postmenopausal Asian women who had not received prior systemic treatment and presented with advanced breast cancer, positive hormone receptors, and HER-2 negative. Here, NR4A1 is linked to breast carcinoma.